Search research articles
Contact Us
Filters
Showing results (111-120 of 120) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 120 results.
Oncology
|
August 10, 2005
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma
E Chamorey, R Gressin, F Peyrade, et al.
Bone Marrow Transplantation
|
September 26, 2001
Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy
M Mohty, N Fegueux, C Exbrayat, et al.
Leukemia
|
June 9, 1999
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients
R Bouabdallah, A M Stoppa, J F Rossi, et al.
Bone Marrow Transplantation
|
August 3, 2006
Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients
P Quittet, P Ceballos, E Lopez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
F Morschhauser, C Recher, N Milpied, et al.
Bone Marrow Transplantation
|
August 23, 2005
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects
J-F Rossi, N Fegueux, Z Y Lu, et al.
Oncogene
|
May 30, 2006
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma
K Mahtouk, F W Cremer, T Rème, et al.
European Cytokine Network
|
March 8, 2000
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission
D Blaise, M Attal, J Reiffers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2004
Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia
J-F Rossi, A van Hoof, K de Boeck, et al.
Oncogene
|
September 1, 2009
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis
A Seckinger, T Meissner, J Moreaux, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 120) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 120 results.
Oncology
|
August 10, 2005
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma
E Chamorey, R Gressin, F Peyrade, et al.
Bone Marrow Transplantation
|
September 26, 2001
Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy
M Mohty, N Fegueux, C Exbrayat, et al.
Leukemia
|
June 9, 1999
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients
R Bouabdallah, A M Stoppa, J F Rossi, et al.
Bone Marrow Transplantation
|
August 3, 2006
Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients
P Quittet, P Ceballos, E Lopez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
F Morschhauser, C Recher, N Milpied, et al.
Bone Marrow Transplantation
|
August 23, 2005
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects
J-F Rossi, N Fegueux, Z Y Lu, et al.
Oncogene
|
May 30, 2006
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma
K Mahtouk, F W Cremer, T Rème, et al.
European Cytokine Network
|
March 8, 2000
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission
D Blaise, M Attal, J Reiffers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2004
Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia
J-F Rossi, A van Hoof, K de Boeck, et al.
Oncogene
|
September 1, 2009
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis
A Seckinger, T Meissner, J Moreaux, et al.
Page
of 12